Difference between revisions of "Team:NUDT CHINA/HP/Silver"

Line 94: Line 94:
 
         <div class="content" style="width: 74%">
 
         <div class="content" style="width: 74%">
 
          
 
          
 +
  
  
Line 393: Line 394:
 
     <h1 style="font-family: Monad; " align="left">Interviews concerned on important application fields</h1>
 
     <h1 style="font-family: Monad; " align="left">Interviews concerned on important application fields</h1>
 
     <p>Nowadays, miRNA inhibitors play an important role in medical treatment. To know more information of miRNA antagonist therapy, we interviewed professor and teaching assistant in different medical universities.</p>
 
     <p>Nowadays, miRNA inhibitors play an important role in medical treatment. To know more information of miRNA antagonist therapy, we interviewed professor and teaching assistant in different medical universities.</p>
     <div class="pure-g" style="width: 100%; height: 100%; overflow: hidden;" >
+
     <div style="width: 100%; height: 100%; overflow: hidden;" >
 
     <div style="display:inline-block;letter-spacing:normal;word-spacing:normal;vertical-align:top;left:0%; width: 44%;text-indent: 0;"><img width="100%" src="https://static.igem.org/mediawiki/2017/5/5f/T-NUDT_CHINA-Silver2.jpg" alt="">
 
     <div style="display:inline-block;letter-spacing:normal;word-spacing:normal;vertical-align:top;left:0%; width: 44%;text-indent: 0;"><img width="100%" src="https://static.igem.org/mediawiki/2017/5/5f/T-NUDT_CHINA-Silver2.jpg" alt="">
 
     <p>Li Ling: Professor and master’s supervisor of biochemistry and molecular biology department, school of Basic Medical Sciences, Southern Medical University, his main research direction is molecular mechanism of bone metastasis in tumor.</p>
 
     <p>Li Ling: Professor and master’s supervisor of biochemistry and molecular biology department, school of Basic Medical Sciences, Southern Medical University, his main research direction is molecular mechanism of bone metastasis in tumor.</p>
Line 419: Line 420:
 
     <center><img style="width: 70%" src="https://static.igem.org/mediawiki/2017/7/7d/T-NUDT_CHINA-Silver5.jpg" alt=""></center>
 
     <center><img style="width: 70%" src="https://static.igem.org/mediawiki/2017/7/7d/T-NUDT_CHINA-Silver5.jpg" alt=""></center>
 
      
 
      
 +
 +
 +
 +
 +
 +
 +
  
  

Revision as of 12:13, 30 October 2017

Silver

Scientific researches and the masses should never be separated; in fact, there are close interactions between the two. It is hard for a product serve human well if it was made in a closed door.

Part one: Absorb nutrients from the outside world

Many of Chinese students are taught to study alone in order to avoid external disturbances, but it is better to listen to outside voices when doing researches. For just standing on others’ shoulders will lifted a project a lot. This part contains:

Consultation with expert

Staying in the lab won't let us know what technical issues of production and circulation should be considered, an experienced CTO of a biology company will offer really useful advice. Click here for detail!

Product evaluation

We investigated similar products available on the market, and scored our product. Click here to see what makes our product stands out in the market.

Interviews concerned on important application fields

Our project is mainly for academic uses. However, miRNA inhibitors’ role on medical treatment cannot be ignored but another main possible application of our product. Click here to see more information of the interviews.

Cooperation among groups:

In the end of August, we attended Conference of China iGEAMer Community, idea exchange meet for China region).click here to see what we have done!

Part two: Bear social responsibility

This year our project is to develop a novel approach for miRNA inhibiting, but that is not all. As an integrated project, in addition to pure research, it has several tasks needed to be done in practice:

Open that black box

Scientific research has never belonged to only a few people; we are responsible for science popularization of our product and its related contents. This year we did something different! Click here to check them out.

Moving our glow sticks for synthetic biology

Participating in a synthetic biology competition, we wanted to exchange our ideas on synthetic biology with other interested schoolmates, thus we gave a presentation carefully prepared to them. Click here for detail.

Attentions on policy-making

So far, no policy mentioned how to standardize the microRNA antagonist therapy has been made, so we will have to wait for it, however, we consulted professors and had a general idea of policy. Want to see? Click here.

Consultation with expert

We went to GenetalksGenetalks is founded in Santiago by a team of young scientists in North America. Since 2009, the clinical transformation of gene testing has been carried out, and it was formally established in Beijing in 2014. With the core of gene technology and other advanced technologies such as information technology and machine learning, the company is committed to technological innovation, application development and services in the field of medicine and health.Hope to receive some professional、market-based suggestions from technicians there, and we were lucky enough to have their technical director Dr. Song Zhuo interviewed. As the CTO, he really considered more than we students, which inspired us a lot.

The most important point we realized lays on safety. If a product or a technology is put into use, the very first thing is to ensure its safety. Thus, he put forward two questions:

  • Will the sponge affect the normal function of cells?
  • Will MicroRNA inhibitor work in positive correlation with level gradient?
  • These provided us new ideas of safety inspection of product beyond the mainline; to fully solve these questions, we added cytotoxicity test and concentration gradient experiment to our future work.

    As for application, he mentioned the market of MicroRNA inhibitor is not limited to research or the treatment of human diseases, agriculture and animal husbandry are also potential and untapped areas for MicroRNA inhibitor. Moreover, market sense is also important for a project; a streamlined and efficient experimental method with a lower cost will make our project more popular.

    Product evaluation

    Prices of similar products

    We made a research on the prices of similar products, and we summed up the results in the following table, this table can roughly show the market prices for miRNA inhibitors existed:

    Company

    Product

    product's name

    Price(rmb)

    Sigma Aldrich

    TuD RNA

    MISSION Lenti microRNA Inhibitor

    6,961.50

    Guangzhou RiboBio Co.

    micrOFF™ miRNA Inhibitors are synthetic antisense oligonucleotides, which is complement to mature miRNAs sequence , for loss-of-function studies of miRNAs.

    micrOFF miRNA inhibitor

    500/nmol

    Shanghai Integrated Biotech Solutions Co.,Ltd.

    it is a special designed RNA molecule that can bind with specific miRNA.

    miRNA inhibitors

    300(2OD),500(4OD)

    Suzhou GenePharma Co.

    an 21-23nt RNA molecule, and was Inhibitoryeffectsof2'-O·—Methoxyethyl-Modified ,can serves as an efficiently microRNA inhibitor

    GMR-miRTM microRNA inhibitors

    350(2OD)

           

    Biomics Biotechnologies.

    This is a miRNA inhibitor, which is especially chemical modified, so that it can serves as an efficiently and specifically inhibitor.

    miRNA inhibitor

    650/10nmol

    BIONEER Trade(Shanghai) Co.,Ltd.

    This specially designed RNA molecule, which has been specially modified, can bind with specific miRNA.

    ccuTarget™ miRNA Inhibitor

    5 n mole

    368

    10 n mole

    544

    20 n mole

    720

    GeneCopoeia Inc

    This specially designed RNA molecule, which has been specially modified, can bind with specific miRNA.

    miArrest™ miRNA inhibitor

    4000-12000

    Cost evaluation of our own product

    Name of reagents

    Unit price

    Use level

    Equivalent

    Oligo

    $0.12 / base

    25.4 bases

    $0.000302

    EcoR I

    $19.55/4000U(15U/µL)

    0.1µL

    $0.0073

    Spe I

    $19.55/150U(10U/µL)

    0.1µL

    $0.13

    T4 Polynucleotide Kinase

    $25.87/200U(10U/µL)

    0.2µL

    $0.26

    T4 DNA ligase

    $25.87/28000U(350U/µL)

    1µL

    $0.32

    2×Tap Master Mix

    $102.27 / 5mL(3 pieces/mL)

    10µL

    $0.05

    Tiangen Plasmid Microkit Kit

    $102.27 / 200 times

    One time

    $0.51

     

    Interviews concerned on important application fields

    Nowadays, miRNA inhibitors play an important role in medical treatment. To know more information of miRNA antagonist therapy, we interviewed professor and teaching assistant in different medical universities.

    Li Ling: Professor and master’s supervisor of biochemistry and molecular biology department, school of Basic Medical Sciences, Southern Medical University, his main research direction is molecular mechanism of bone metastasis in tumor.

    Q: A major application direction of our project is microRNA antagonist therapy. What impact do you think it will bring to the basic treatment? And what new challenges will it pose to hospitals and doctors?

    A: News showed that the FDA program approved gene therapy technology and the first gene therapy was expected to be approved in January 2018. In addition, an RNAi (RNA interference) drug has entered the main clinical endpoint of phase three clinical trials. MicroRNA and its antagonist therapy is a promising new technique for treating diseases at gene level. With the wide application of this technology in clinic, many clinical drugs and therapies harmful to human body will face elimination. However, new therapies will have their own advantages, and shortcomings, old things cannot fade away immediately, new things will also face many challenges to retain. Hospitals and clinicians should keep up with the breakthrough of medical technology, enrich the knowledge reserve of gene therapy technology and its treatment, and meet the new challenges at any time to serve the human health.

    Q: Systematic drug-given method of the current microRNA antagonist therapy may induce adverse consequences, such as complement activation, hepatotoxicity, and so on. Do you think that means that this therapy is still not mature? How about the acceptance of these risks?

    A:Obviously, microRNA antagonists can treat diseases from the source by inhibiting the expression of target genes at the gene level, and have shown good efficacy in a large number of clinical studies and clinical trials. As you described, some of the side effects associated with new therapies also exist. There may be individual differences, and there may be some deficiencies need to be improved. When the microRNA antagonist therapy enters clinical trials, FDA (sFDA) approval process, the treatment effect and its risk will be evaluated, and then mature therapy will be approved. For the new treatment, the patient's acceptance may be different, most of them need to be informed before the medication, and it is necessary to sign the informed consent.

    Tu Shuo: Teaching assistant of biochemistry and molecular biology department of Nanchang University, her main research direction is tumor cell apoptosis.

    Q: what role do microRNAs play in medical treatment nowadays?A: MicroRNAs are more used in early cancer detection at present, they may appear as adjuvant treatment in the future.

    Q: What new challenges do you think microRNAs antagonist might pose to future medical scheme design?

    A: The most important challenge is personalized care, it would be ideal to design treatments based on the patient's genetic sequence. Gene therapy is nothing more than specificity, so the key is to find the most specific impact factors or biomarkers of disease, and change it to reach the therapeutic effect of disease. Therefore, the effect of antagonist treatment is determined by whether the first stage can find the key target.

    Q: Systematic drug-given method of the current microRNA antagonist therapy may induce adverse consequences, such as complement activation, hepatotoxicity, and so on. Do you think that means that this therapy is still not mature? How about the acceptance of these risks?

    A: Liver toxicity depends on whether the drug itself is toxic or only after metabolized in vivo, or it is only toxic to the individual populations. If the drug itself is toxic or metabolized to produce toxicity, then it is necessary to control the dosage strictly and conduct periodic blood biochemical examination during the drug use, as for complement activation, make clear whether it is due to individual specificity or universal situation. It can be taken simultaneously with drugs that inhibit complement activation or optimize its structure.so once something unexpected happens, we can stop using the drug or replace therapeutic plan. There are many drugs have liver toxicity, so the drug can still be used in clinic even it has liver toxicity.

    Cooperation among groups

    In the end of August, we attended FAFU_CCICFujian Agricultural and Forestry University Conference of China iGEAMer Community, and spent three days there.

    The meetup is held for teams to share ideas and help each other. When communicating with other teams, we heard team BGIC-Union need plasmids which we designed a year before, then we decided to offer the plasmids, click here for details in collaboration page. In a few words, we had a fulfilling time in CCIC!

    Exactly at this meeting, we found the project of team Lanzhou has some relevance to our project; their project is A novel method in controlling weeds and pests by tandem RNA Interference. Then we made communication in specific experiments at the venue. Thanks to CCIC, it provided a nice platform for teams to get together, know each other and discuss the possibilities of cooperation.

    After CCIC, we made deeper online interaction with team Lanzhou with more team member participated.

    In this online interaction, we talked about each teams’ project mechanism, new situations encountered in experiments and progress of modeling and human practice.